SEARCH:   Advanced

Blood, 1 July 2008, Vol. 112, No. 1, pp. 45-52. Prepublished online as a Blood First Edition Paper on April 28, 2008; DOI 10.1182/blood-2008-01-134858. This Article Full Text (PDF) All Versions of this Article: blood-2008-01-134858v1 112/1/45    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rollison, D. E Articles by List, A. F Search for Related Content PubMed PubMed Citation Articles by Rollison, D. E Articles by List, A. F Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 18, 2008 Accepted March 17, 2008 Epidemiology of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders in the United States, 2001-2004: Utilizing Data from the NAACCR and SEER Programs Dana E Rollison*, Nadia Howlader, Martyn T Smith, Sara S Strom, William D Merritt, Lynn A Ries, Brenda K Edwards, and Alan F List Cancer Prevention and Control Division, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States Contractor to the National Cancer Institute, National Cancer Institute, Bethesda, MD, United States School of Public Health, University of California, Berkeley, CA, United States Epidemiology, MD Anderson Cancer Center, Houston, TX, United States Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, United States Surveillance Research Program, National Cancer Institute, Bethesda, MD, United States Hematologic Malignancies Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States * Corresponding author; email: dana.rollison{at}moffitt.org. Reporting of myelodysplastic syndromes (MDS) and chronic myeloproliferative disorders (CMD) to population-based cancer registries in the U.S. was initiated in 2001. In this first analysis of data from the North American Association of Central Cancer Registries (NAACCR), encompassing 82% of the U.S. population, we evaluated trends in MDS and CMD incidence, estimated case numbers for the entire U.S., and assessed trends in diagnostic recognition and reporting. Based on >40,000 observations, average annual age-adjusted incidence rates of MDS and CMD for 2001-2003 were 3.3 and 2.1 per 100,000, respectively. Incidence rates increased with age for both MDS and CMD (p<0.05) and were highest among Whites and non-Hispanics. Based on follow-up data through 2004 from the Surveillance Epidemiology and End Results Program, overall relative 3-year survival rates for MDS and CMD were 45% and 80%, respectively, with males experiencing poorer survival than females. Applying the observed age-specific incidence rates to U.S. Census population estimates, approximately 9,700 MDS cases and 6,300 CMD cases were estimated for the entire U.S. in 2004. MDS incidence rates significantly increased with calendar year in 2001-2004, and only 4% of cases were reported to registries by physicians offices. Thus, MDS disease burden in the U.S. may be underestimated. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Tefferi and J. W. Vardiman Myelodysplastic Syndromes N. Engl. J. Med., November 5, 2009; 361(19): 1872 - 1885. [Full Text] [PDF] M. L. Chen, T. D. Logan, M. L. Hochberg, S. G. Shelat, X. Yu, G. E. Wilding, W. Tan, G. C. Kujoth, T. A. Prolla, M. A. Selak, et al. Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction Blood, November 5, 2009; 114(19): 4045 - 4053. [Abstract] [Full Text] [PDF] A. M. Vannucchi, G. Masala, E. Antonioli, M. Chiara Susini, P. Guglielmelli, L. Pieri, L. Maggi, S. Caini, D. Palli, C. Bogani, et al. Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms Cancer Epidemiol. Biomarkers Prev., July 1, 2009; 18(7): 2068 - 2073. [Abstract] [Full Text] [PDF] X. Ma, U. Lim, Y. Park, S. T. Mayne, R. Wang, P. Hartge, A. R. Hollenbeck, and A. Schatzkin Obesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US Cohort Am. J. Epidemiol., June 15, 2009; 169(12): 1492 - 1499. [Abstract] [Full Text] [PDF] F. Girodon, G. Bonicelli, C. Schaeffer, M. Mounier, S. Carillo, I. Lafon, P. M. Carli, I. Janoray, E. Ferrant, and M. Maynadie Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study Haematologica, June 1, 2009; 94(6): 865 - 869. [Abstract] [Full Text] [PDF] A. M. Vannucchi, P. Guglielmelli, and A. Tefferi Advances in Understanding and Management of Myeloproliferative Neoplasms CA Cancer J Clin, May 1, 2009; 59(3): 171 - 191. [Abstract] [Full Text] [PDF] G. Garcia-Manero Standard-of-care Approaches for Myelodysplastic Syndromes ASCO Educational Book, January 1, 2009; 2009(1): 408 - 412. [Abstract] [Full Text] [PDF] F. Passamonti, E. Rumi, L. Arcaini, E. Boveri, C. Elena, D. Pietra, S. Boggi, C. Astori, P. Bernasconi, M. Varettoni, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients Haematologica, November 1, 2008; 93(11): 1645 - 1651. [Abstract] [Full Text] [PDF] Incidence of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders Journal Watch Oncology and Hematology, September 9, 2008; 2008(909): 2 - 2. [Full Text]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020